Imagion Biosystems Ltd
Company Profile
Business description
Imagion Biosystems Ltd operates in the field of non-invasive detection of specific solid tumor cancers by use of magnetic nanoparticles. Its principal continuing activities consisted of Nanotechnology; Biotechnology; Cancer Diagnostics; and Medical Imaging using Magnetic Resonance and Superparamagnetic Relaxometry. The company only operating segment - Research and Development. Its principal business activities consist of nanotechnology, biotechnology, cancer diagnostics, and medical imaging using Superparamagnetic Relaxometry. In addition, the company is engaged in the research and development of its clinical phase lead product which is intended for the detection and staging of metastatic HER2 breast cancer.
Contact
5601 Oberlin Drive
Suite 100
San DiegoCA92121
USAT: +1 855 564-5264
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 December 2025
Employees
Stocks News & Analysis
stocks
Ask the analyst: Can this big Covid loser scale its former heights?
stocks
The fight for Insignia continues
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,660.40 | 31.30 | 0.36% |
| CAC 40 | 7,927.62 | 35.01 | 0.44% |
| DAX 40 | 21,394.93 | 16.60 | -0.08% |
| Dow JONES (US) | 44,424.25 | 140.82 | -0.32% |
| FTSE 100 | 8,502.35 | 62.85 | -0.73% |
| HKSE | 20,066.19 | 365.63 | 1.86% |
| NASDAQ | 19,954.30 | 99.38 | -0.50% |
| Nikkei 225 | 39,931.98 | 26.89 | -0.07% |
| NZX 50 Index | 13,024.70 | 35.38 | -0.27% |
| S&P 500 | 6,101.24 | 17.47 | -0.29% |
| S&P/ASX 200 | 8,408.90 | 30.20 | 0.36% |
| SSE Composite Index | 3,252.63 | 22.46 | 0.70% |